Redcare Pharmacy (XTRA:RDC) Following H1 2026 Results, Is The Valuation Case Still Holding Up?

Redcare Pharmacy (XTRA:RDC) has drawn fresh attention after reporting half year 2026 results that combined higher sales with a wider net loss, while also confirming its full year revenue growth guidance.

See our latest analysis for Redcare Pharmacy.

Redcare Pharmacy’s recent half year update comes after a mixed share price pattern, with a 1 day share price return of 1.75% and a 90 day share price return of 38.85%, but a 1 year total shareholder return that declined 37.11%. This suggests short term momentum has improved while longer term holders are still facing pressure.

If this kind of earnings driven move has your attention, it can be a good moment to widen your watchlist and look at other potential growth stories through the 107 top founder-led companies

Redcare Pharmacy now sits between a sharp recent rebound and still heavy longer term losses. The key issue is whether the valuation already reflects that shift in sentiment or still leaves meaningful upside on the table.

Preferred Price-to-Sales of 0.4x: Is it justified?

Simply Wall St currently flags Redcare Pharmacy as good value overall, yet its preferred multiple check paints a different picture. On a P/S basis, the stock is described as expensive despite the last close at €63.90.

The preferred multiple here is the price-to-sales ratio, which compares Redcare Pharmacy’s market value to its annual revenue. For a business focused on online pharmacy and retail products, P/S is often used when earnings are weak or negative, as it anchors valuation to sales rather than profit.

Redcare Pharmacy is assessed as expensive on this measure with a P/S of 0.4x against an estimated fair P/S of 0.2x. That suggests the current pricing sits above the level the fair ratio model points to and would need to compress if the share price moved closer to that fair multiple. The same 0.4x P/S is also described as expensive versus both peer averages and the broader European Consumer Retailing industry. This reinforces the message that the stock trades at a premium to what the P/S fair ratio indicates.

Explore the SWS fair ratio for Redcare Pharmacy

Result: Price-to-Sales of 0.4x (OVERVALUED)

However, Redcare Pharmacy still carries clear risks, including ongoing net losses of €42.0m and a share price that remains under pressure over 1 and 5 years.

Find out about the key risks to this Redcare Pharmacy narrative.

Another view on Redcare Pharmacy’s value

The P/S gap suggests Redcare Pharmacy looks expensive on sales, yet the SWS DCF model points in the opposite direction. At €63.90, the stock is described as trading 81.9% below an estimated future cash flow value of €353.90. That reads as a deep discount. Which signal appears more informative in your analysis?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Redcare Pharmacy for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 249 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals around Redcare Pharmacy can feel confusing, so it helps to move quickly and check the underlying data for yourself. To see both the risks that investors are wary of and the rewards they are optimistic about, review the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Redcare Pharmacy?

If Redcare Pharmacy has sharpened your focus, now is a smart time to broaden your opportunity set using targeted stock lists that match your goals.

• Target potential mispricing and see which companies combine quality with attractive pricing by reviewing the 249 high quality undervalued stocks.
• Build a sturdier core for your portfolio and focus on financial strength with the solid balance sheet and fundamentals stocks screener (424 results).
• Aim to get ahead of the crowd and hunt for future standouts through the screener containing 547 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com